The present invention relates to the use of the A20-binding inhibitor of
NF-.kappa.B activation (ABIN), or a functional fragment or variant
thereof to protect against TNF-induced liver failure, such as viral
hepatitis and alcoholic liver disease. More particularly, it relates to
the prevention of the toxic effects of said diseases, including
lethality, by overexpressing ABIN.